Laura Girardi on Anticoagulant Treatment for Isolated Distal DVT: Finally Our Official Paper Is Out!
Laura Girardi, Clinical and Research Thrombosis Fellow at The Ottawa Hospital, shared on LinkedIn:
”Finally our official paper is out!
An updated systematic review with meta-analysis on management of isolated distal DVT (IDDVT).
Thanks to my fabulous colleagues to have made it possible.
Efficacy outcomes (recurrent DVT, PE, proximal progression of IDDVT and PTS) and safety outcomes (major bleeding and CRNMB) are mainly presented depending on different approaches:
1. No anticoagulation
2. Short duration of anticoagulation (<6 weeks)
3. Long duration (6-12 weeks)
4. Extended-anticoagulation (>12 weeks)
- Patients receiving short courses of anticoagulation had higher risk of recurrent VTE (RR=2.72; 95% CI: 1.19-6.23) and proximal progression (RR=3.86; 95% CI: 1.77-8.43) than patients receiving long anticoagulation, with similar bleeding risk in patients with IDDVT.
- Anticoagulation seemed associated with lower risk of recurrent VTE and proximal progression, and similar bleeding risk compared to no anticoagulant treatment.
- The incidence of PTS was 30% in untreated patients, 11% in short, and 0% in long anticoagulation.
- Long-term treatment duration appeared to be more effective.
Please find more details (e.g. dose and type of anticoagulation, baseline patients’ risks, etc.) in the full text!”
Read the full article in Haematologica.
Article: Anticoagulant treatment for isolated distal deep vein thrombosis: a systematic review and meta-analysis
Authors: Matteo Guarascio, Emanuele Valeriani, Laura Girardi, Matteo Candeloro, Arianna Pannunzio, Ilaria Maria Palumbo, Marcello Di Nisio, Walter Ageno
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening